EGLN3 and neoplasm: Tumor development altered fatty acid partitioning in the fatty liver via inhibiting prolyl hydroxylase domain (PHD)3 expression, which results in function loss of cytotoxic CD8+ T cells and impaired anti-tumor function (27).